At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
In Brief
A Phase 2 clinical trial evaluating Abiraterone Acetate, Prednisone, and 2 other interventions for Prostate Cancer. Completed, enrolled 190 participants across 1 site.
Detailed Summary
You are being asked to take part in this study because you have prostate cancer that has spread to other parts of the body. This is an investigational study. Prednisone is FDA-approved and commercially available. Abiraterone acetate is FDA-approved and commercially available, but is still being researched. Sunitinib malate is FDA-approved for the treatment of gastrointestinal tumors and renal cell carcinoma, and dasatinib is FDA approved and commercially available for certain types of leukemia. The use of these drugs in prostate cancer and in combination with abiraterone acetate and prednisone is investigational. Up to 180 patients will be enrolled in this study. All will be enrolled at MD Anderson.
Study Details
Timeline
Interventions
1000 mg by mouth each day of a 28 day cycle.
5 mg by mouth twice daily of a 28 day cycle.
37.5 mg by mouth daily for two weeks followed by a week of rest in a 28 day cycle.
100 mg by mouth each day of a 28 day cycle.